Biochemistry

Tickets On Sale for 45th Annual Freed-Hardeman University's Makin' Music: "No Going Back"

Retrieved on: 
Friday, February 25, 2022
Human, Music, Baby Makin' Music, Gold, Education, Biochemistry, COVID-19, Bible, No Going Back, Child, Friends, FHU, R. Brooke Jackson, Student, Makin, Green, Freed–Hardeman University, Nightclub, Party

The three weekend performances will be Friday at 7:30 p.m. and Saturday at 2 p.m. and 7:30 p.m. Tickets may be purchased at makinmusictickets.com.

Key Points: 
  • The three weekend performances will be Friday at 7:30 p.m. and Saturday at 2 p.m. and 7:30 p.m. Tickets may be purchased at makinmusictickets.com.
  • A team of hosts and hostesses, emcees and the Makin' Music Show Band will entertain the audience between the competitive entries.
  • Prospective students and their families are invited to attend FHU's Maroon & Gold Day Saturday, April 9; they may register at fhu.edu/maroonandgold.
  • "We are thrilled to once again welcome a full capacity, in-person audience to Loyd Auditorium this April," Tony Allen, Makin' Music producer, said.

Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

Retrieved on: 
Thursday, February 24, 2022
Failure, Security (finance), Company, Senior advisor, Compugen, Senior, Clinical pharmacology, R, Nasdaq, Private Securities Litigation Reform Act, Research, Bispecific monoclonal antibody, Board of directors, McKinsey & Company, Retirement, Risk, Board, Biochemistry, Novartis, TIGIT, Drug development, IO, Pharmacology, U.S. Securities and Exchange Commission, Bristol Myers Squibb, Terminology, Pharmaceutical Research and Manufacturers of America, University of Nijmegen (1655–80), TEL, AstraZeneca, D, Pharmacometrics, Atomic Energy Regulatory Board, Compugen (Israeli company), PDUFA, Forward-looking statement, Patient, Immunotherapy, University, Annual report, Industry, Science and technology in Asia, Acquisition, FDA, SEC, Pharmaceutical industry, Safety, PVRIG, Bayer, Biology

In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors.

Key Points: 
  • In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors.
  • "I am delighted to welcome Math to Compugen's Board," said Paul Sekhri, Chairman of the Board.
  • I would also like to thank Jean-Pierre who will end his tenure as a director on March 1, 2022, for his contributions to Compugen."
  • "I had the privileged opportunity to play a key role in the introduction of transformational immune-based therapies that are today changing patients' lives.

Municipal Finance & Services Corp. Adds Investment Banker Lacarya Scott to Advisory Board

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Wharton School of the University of Pennsylvania, FINRA, AB, Life Technologies, Board, Caxton Associates, CFA, Biotechnology, University, Chartered, Chartered Financial Analyst, Princeton University, Tungsten, Invitrogen, Advisory Committee, Strategic management, MS, Pi bond, Biochemistry, University of Pennsylvania, M&A, Financial services, Biophysics, New York University, Biology, Engineering

WOODBRIDGE, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Municipal Finance & Services Corp (MFSC) is very pleased to announce that Lacarya D. Scott has joined the company's Advisory Committee.

Key Points: 
  • WOODBRIDGE, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Municipal Finance & Services Corp (MFSC) is very pleased to announce that Lacarya D. Scott has joined the company's Advisory Committee.
  • Mr. Scott, Managing Partner of Tungsten Advisors, was instrumental in MFSC's equity funding and brings more than 19 years of global macro, hedge fund and investment experience to Municipal Finance.
  • He holds the Chartered Financial Analyst (CFA) designation and FINRA licenses: Securities Industry Essentials, Series 79.
  • The company looks forward to his active involvement and professional contributions in assisting it achieving its financial goals in the government sector.

GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer

Retrieved on: 
Wednesday, February 23, 2022
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Cell, Annual report, McKesson Corporation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Memorial Sloan Kettering Cancer Center, Risk, E-selectin, Clinical research coordinator, Education, BA, Novartis, AML, Hematology, Columbia University, Bone marrow, Miami University, Inc. (magazine), Food, Adult, Senior, Breakthrough therapy, Molecular biology, FDA, Nasdaq, Forward-looking statement, Patient, CXCR4, AbbVie, Form 10-K, SEC, Management, Pharmaceutical industry, Venetoclax, Glycomimetic, Biochemistry, Marketing, Microbiology, Uproleselan (GMI-1271), GlycoMimetics, Inc., UPROLESELAN (GMI-1271), GLYCOMIMETICS, INC.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer.
  • Bruce brings to GlycoMimetics a wealth of oncology / hematology expertise particularly in leading commercial and development activities across multiple launches.
  • Prior to that, Bruce spent 25 years in oncology, mostly at Novartis, with roles such as Vice President & Global Franchise Head, Malignant Hematology; Vice President & Global Disease Leader, Leukemia Franchise (Including Midostaurin); and US Oncology brand leader.
  • Bruce was also Vice President, Global Commercial Development, Oncology at AbbVie and worked on Venetoclax life cycle management.

Frazier Life Sciences Adds Highly Experienced Biopharmaceutical Executive to Team

Retrieved on: 
Tuesday, February 22, 2022
Professional Services, Health, Finance, General Health, Pharmaceutical, Biotechnology, Commercial, NASDAQ, Therapy, Sanofi, Harvard College, Hematology, Senior advisor, Sale, Johnson & Johnson, Acquisition, List of life sciences, Drug discovery, Harvard University, Doctor of Philosophy, Initial public offering, Management, Pharmaceutical industry, Fine chemical, Biochemistry, Chemistry

She is a highly experienced biopharmaceutical executive who will help us identify and evaluate investment opportunities.

Key Points: 
  • She is a highly experienced biopharmaceutical executive who will help us identify and evaluate investment opportunities.
  • Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals.
  • Since 2005, 61 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As.
  • The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.

University of Detroit Mercy announces the appointment of Donald B. Taylor, Ph.D., as the institution's 26th president

Retrieved on: 
Tuesday, February 22, 2022
University, Outline of health sciences, Partnership, University of Detroit Mercy, News, Accreditation, Board, Time, University of Utah College of Science, Biology, U.S. News & World Report Best Colleges Ranking, University of Texas Health Science Center at Houston, Biochemistry, Catholic higher education, Cabrini University, Cabrini, Catholic (term), Money (magazine), Multimedia, Molecular biology, John Paul the Great Catholic University, College, Benedictine University, Faculty, Research, Doctor of Philosophy, Program, U.S. News & World Report, Department, Medicine, Management, Trustee, Education, Benedictines, Cell, Science

DETROIT, Feb. 22, 2022 /PRNewswire/ -- University of Detroit Mercy's (Detroit Mercy) Board of Trustees today announces that Donald B. Taylor, Ph.D., has been named the institution's 26th president.

Key Points: 
  • DETROIT, Feb. 22, 2022 /PRNewswire/ -- University of Detroit Mercy's (Detroit Mercy) Board of Trustees today announces that Donald B. Taylor, Ph.D., has been named the institution's 26th president.
  • During Taylor's tenure as president, Cabrini ranked among the top 40 Most Transformative Colleges in the nation by Money Magazine.
  • In 2019, the University was also ranked as one of the Best Northern Universities by U.S. News & World Report's "Best Colleges Edition."
  • Prior to his appointment as president at Cabrini, Taylor was provost and vice president for Academic Affairs at Benedictine University in Lisle, Ill, near Chicago, from 2008-14.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, HCV, Virus, Severe acute respiratory syndrome coronavirus 2, Dengue virus, Biochemistry, ID, COVID-19, Company, RSV, Virology, Biology, Respiratory syncytial virus, Atea, Nasdaq, Patient, Degenerative disease, RNA, Vaccine

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, February 28, 2022 at 4:30 p.m.

Key Points: 
  • BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, February 28, 2022 at 4:30 p.m.
  • ET to report financial results for the fourth quarter and full-year ended December 31, 2021, and to provide a business update.
  • To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least five minutes prior to the start time, and refer to conference ID 7171208.
  • An archived webcast will be available on the Atea website approximately two hours after the event.

Arthur A. Arena, MD is recognized by Continental Who's Who

Retrieved on: 
Monday, February 21, 2022
American Board of Commissioners for Foreign Missions, San Joaquin, San Joaquin General Hospital, Retirement, Hospital, University, Medical College of Wisconsin, Continental, Medical college, Biochemistry, Catholic (term), Emergency medicine, Autonomous university, Medicine, American Board of Obstetrics and Gynecology, ABOG, Ministry of Health (New South Wales), Patient, Bachelor, University of California, Irvine Medical Center, Obstetrics and gynaecology, Certification, Mississippi River, Private practice, Gynaecology, Obstetrics, MD, Science

Arena, MD, is being recognized by Continental Who's Who as an Trusted Healthcare Professional in the Medical field and in acknowledgment of his work in private practice.

Key Points: 
  • Arena, MD, is being recognized by Continental Who's Who as an Trusted Healthcare Professional in the Medical field and in acknowledgment of his work in private practice.
  • Arena, MD, has been in private practice for over two decades, serving the Milwaukee, WI, area.
  • Dr.
  • Dr.

The Switzerland Eye Research Institute Published a Breakthrough Case Report Using Light Exposure and Nutraceuticals for Treating Retinal Degeneration

Retrieved on: 
Wednesday, February 16, 2022
Science, Other Science, Biotechnology, Research, Optical, General Health, Health, Other Health, Drusen, Emerging technologies, Nervous system, CEO, Department, Macular degeneration, Archives Italiennes de Biologie, College, University of Pisa, Translational research, Cell, Light, Pinelli, AMD, Eastern Michigan University College of Health and Human Services, Mitochondrion, Human services, Retina, San Diego State University, University, ATP, Eye, Phytochemical, Medical device, Biochemistry, Medicine

Dr Roberto Pinelli, CEO of the Switzerland Eye Research Institute, announced today the publication of a breakthrough paper in Archives Italiennes de Biologie, one of the oldest journal neurosciences in the world.

Key Points: 
  • Dr Roberto Pinelli, CEO of the Switzerland Eye Research Institute, announced today the publication of a breakthrough paper in Archives Italiennes de Biologie, one of the oldest journal neurosciences in the world.
  • http://www.architalbiol.org/index.php/aib/article/view/159134
    The neurobiology of nutraceuticals combined with light exposure has solved a case of age related macular degeneration, AMD; the drusen disappeared in six months after this treatment called Lugano Protocol- Dr Pinelli said - thanks also to the collaboration with other Institutions.
  • The Department of Chemistry and Biochemistry, and the College of Health and Human Services, San Diego State University, USA are represented by Dr. Violet Vakunseh Bumah.
  • The Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa and IRCCS Neuromed Pozzili, Italy, were represented by Prof. Francesco Fornai.

Artemis Announces Promotion of Olly Forrer to Principal

Retrieved on: 
Wednesday, February 16, 2022
Science Publishing Group, Forrer, Olly, Board, Company, University of Massachusetts Amherst Department of Food Science, Canaccord Genuity, Growth, Multimedia, University, Molecular biology, STC, Bank, Biochemistry, Tech, Artemis

BOSTON, Feb. 16, 2022 /PRNewswire/ -- Artemis, the leading Industrial Tech private equity firm, has announced the promotion of Olly Forrer to Principal.

Key Points: 
  • BOSTON, Feb. 16, 2022 /PRNewswire/ -- Artemis, the leading Industrial Tech private equity firm, has announced the promotion of Olly Forrer to Principal.
  • "We're grateful for Olly's contributions to Artemis and congratulate him on his promotion to Principal."
  • Forrer currently serves on the Artemis portfolio boards of Superior Technical Ceramics (STC), Tekscan, and RM Lucas with previous Board service at BioDot.
  • Before joining Artemis, Olly worked at Canaccord Genuity and AGC Partners in Tech investment banking roles and earned dual B.S.